A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

What is the purpose of this trial?

Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant


Participation Guidelines

Ages: 18 years and older

Gender: Both


Novartis Pharmaceuticals

Start Date: 08/31/2018

End Date: 02/27/2020

Last Updated: 09/04/2018

Study HIC#: 2000022291

Get Involved

For more information about this study, contact:
Courtney Frederick
+1 203-785-6128
courtney.frederick@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image